Industry News
Biotechnology Industry News
Venture capital firm Portal…
Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while also establishing a venture fund to support early-stage life sciences and biotech companies.
After steering positive key…
After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with fleshing out Pfizer’s $43 billion Seagen acquisition into an antibody-drug conjugate empire while accelerating a PD-1xVEGF bispecific
Roche is plugging 710 billion won…
Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting global clinical trials to the East Asian nation.
Bayer has discontinued an…
Bayer has discontinued an early-stage clinical gene therapy for a rare genetic disorder in favor of a similar candidate.
UCB has entered the red-hot T-cell…
UCB has entered the red-hot T-cell engager space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.
The cash will be spread across…
The cash will be spread across four years to fund development of the anti-TL1A antibody duvakitug.
Ono Pharmaceutical subsidiary…
Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline, citing strategic reasons unrelated to the asset’s safety or efficacy.
The FDA has released the rejection…
The FDA has released the rejection letter explaining its recent refusal of Regenxbio’s gene therapy for the rare disease Hunter syndrome, providing further details into the agency’s issues with the biotech’s trial design.
As antibody discovery pipelines…
As antibody discovery pipelines scale, early developability assessment is increasingly used to support smarter candidate prioritization and downstream decision-making.
Theravance Biopharma will lay off…
Theravance Biopharma will lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.
Two new cancer cases have prompted…
Two new cancer cases have prompted Kyowa Kirin to shutter all studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory diseases.
Disc Medicine is laying off a…
Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate.
Biohaven is powering ahead with…
Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn that the company will need to be even stricter with its expenditures.
After cutting down its pipeline…
After cutting down its pipeline just a few months ago, OSE Immunotherapeutics is at it again, this time reorganizing as Boehringer Ingelheim walks away from the biotech’s metabolic dysfunction-associated steatohepatitis (MASH) candidate.
T-cell engager (TCE) specialist…
T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow Candid to trade on the Nasdaq while dumping RallyBio’s own rare disease maternal-fetal medicine assets.
More than a year after first…
More than a year after first agreeing to a reverse merger with Pulmatrix, protein degradation biotech Cullgen has instead opted to be bought by Gyre Therapeutics in a $300 million all-stock acquisition.
Shares of uniQure plummeted more…
Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for Huntington’s disease.
The FDA has liberated the second…
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following serious liver toxicity.
United Therapeutics has linked a…
United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial, setting the company up to seek FDA approval in pulmonary arterial hypertension
BioAtla is laying off 70% of its…
BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets.